ArticleCell2023
High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients.
Article in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 51 citations in OpenAlex.
- Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.Blood advances · 2025Trial
- Article
- Drug-microbiome-host interactions: antimicrobial effects of non-antibiotic compounds.Nature reviews. Gastroenterology & hepatology · 2026Review
- Impact of lymphocyte p-glycoprotein activity on development of graft-versus-host disease after stem cell transplantation.International journal of hematology · 2026Article
- Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding.Nature communications · 2026Article
- The intestinal microbiota as a key modulator of acute graft-versus-host disease.Nature reviews. Cancer · 2026Review
- The cancer-microbiome axis: Mechanisms and emerging therapeutic strategies.Seminars in immunopathology · 2026Review
- Article
- Between the Sponge and the Tap-Bacterial Communities at Overlooked Hospital Hygiene Hotspots.Microorganisms · 2026Article
- DynaBiome: interpretable unsupervised learning of gut microbiome dysbiosis via temporal deep models.BMC bioinformatics · 2026Article
- The Japanese gut microbiome: ecology, uniqueness, and impact on health and disease.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2026Review
- Pharmacodynamic Material Basis of the Components of FourJournal of hepatocellular carcinoma · 2026Article
- "The antibiotic paradox" in allogeneic stem cell transplantation.Bone marrow transplantation · 2025Article
- The microbial metabolite desaminotyrosine protects against graft-versus-host disease via mTORC1 and STING-dependent intestinal regeneration.Nature communications · 2025Article
- The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.Nature reviews. Drug discovery · 2025Review
- Ecological management of the microbiota in patients with cancer.Nature reviews. Clinical oncology · 2025Review
- Microbiome-based prediction of allogeneic hematopoietic stem cell transplantation outcome.Genome medicine · 2025Article
- Exploring the Gut and Oral Microbiomes in Psychoactive Substance Use: A Scoping Review of Clinical Studies.Journal of neurochemistry · 2025Article
- Investigating postbiotics as innovative adjuvants: deciphering the gut-breast connection in breast Cancer therapy, from gut microbiome to personalized medicine.Molecular biology reports · 2025Review
- A consortium of seven commensal bacteria promotes gut microbiota recovery and strengthens ecological barrier against vancomycin-resistant enterococci.Microbiome · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
32 authors at 4 institutions in 1 country.
Funding
Abstract
Discerning the effect of pharmacological exposures on intestinal bacterial communities in cancer patients is challenging. Here, we deconvoluted the relationship between drug exposures and changes in microbial composition by developing and applying a new computational method, PARADIGM (parameters associated with dynamics of gut microbiota), to a large set of longitudinal fecal microbiome profiles with detailed medication-administration records from patients undergoing allogeneic hematopoietic cell transplantation. We observed that several non-antibiotic drugs, including laxatives, antiemetics, and opioids, are associated with increased Enterococcus relative abundance and decreased alpha diversity. Shotgun metagenomic sequencing further demonstrated subspecies competition, leading to increased dominant-strain genetic convergence during allo-HCT that is significantly associated with antibiotic exposures. We integrated drug-microbiome associations to predict clinical outcomes in two validation cohorts on the basis of drug exposures alone, suggesting that this approach can generate biologically and clinically relevant insights into how pharmacological exposures can perturb or preserve microbiota composition. The application of a computational method called PARADIGM to a large dataset of cancer patients' longitudinal fecal specimens and detailed daily medication records reveals associations between drug exposures and the intestinal microbiota that recapitulate in vitro findings and are also predictive of clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.